Profitelligence Profitelligence · Filing Ledger Open BSX research →

Form 8-K · Current Report · Filed 2026-07-27

Boston Scientific Announces New Global Restructuring Plan

On July 21, 2026, Boston Scientific Corporation announced a new global restructuring program, the 2026 Restructuring Plan, aimed at driving sustained cost efficiencies and enabling continued growth.

Filer
Boston Scientific Corporation BSX · NYSE
Filed
Accession
0000885725-26-000049
CIK
0000885725
Signal
Medium impactHealthcare

Details

The plan is expected to result in total pre-tax charges of approximately $700 million to $800 million, with approximately $600 million to $700 million in future cash outlays. The restructuring is expected to reduce gross annual pre-tax expenses by approximately $500 million as benefits are realized. The plan includes supply chain optimization, targeted functional transformation, and organizational structure evolution, with expected headcount reductions. A substantial portion of the savings is expected to be reinvested in strategic growth initiatives.

Items reported

Item events

Reported Item

Restructuring Costs

Market reaction

Close before filing

$44.25

Next session

+4.1%

Since filing

+5.6%

Latest close

$46.73

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from BSX reporting the same item, with the next session's move:

Insider tape

Within 45 days of this filing, BSX insiders reported 3 Form 4 transactions — net selling of $43K.

Full BSX insider history →

About Boston Scientific Corporation

Boston Scientific Corporation, a leading global medical device company, is renowned for developing and supplying innovative health solutions. Its primary function is to design, manufacture, and market medical devices used in interventional medical specialties such as cardiology, peripheral interventions, cardiac rhythm management, endoscopy, urology, and neuromodulation. The company's product offerings significantly impact sectors like health care, particularly those focusing on minimally invasive treatments. Boston Scientific's products help improve the quality of patient care and reduce the need for major surgery, thus playing a crucial role in modern healthcare systems. Their devices contribute to procedures that are less invasive, more effective, and often more economic, supporting better patient outcomes and quicker recovery times. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific provides its products to healthcare providers and institutions worldwide. In the financial markets, Boston Scientific Corporation holds significant influence as a major player in the healthcare industry, contributing to advancements in medical technology and shaping the future of patient care through research and development. Its presence underscores the importance of innovation in medical devices and its role in enhancing healthcare delivery.

Exchange NYSE Industry Medical Devices Company website ↗

Never miss another BSX filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts